Immuno-Oncology

Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses some of the challenges that oncologists may face when administering immunotherapy agents to patients with melanoma.

Many things are happening with payer practices as a result of the plethora of new immuno-oncology agents.

The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of frontline pembrolizumab for the treatment of patients with metastatic non–small cell lung cancer whose tumors do not harbor EGFR or ALK mutations.

Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses immune checkpoint blockade therapies that are currently being used to treat patients with melanoma.

Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses 2 exciting, ongoing phase III randomized trials in melanoma.

Excitement continues to surround the potential role of immunotherapy agents in the treatment of patients with sarcoma, according to Breelyn Wilky, MD.

Several challenges remain in the treatment landscape of soft tissue sarcoma, a disease whose diagnosis can range from one that is quite indolent for patients, to a more life-threatening, metastatic, aggressive cancer.

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the use of immunotherapy in patients with head and neck cancer who have residual disease following treatment with chemotherapy and radiation.

Luciano Mutti, MD, professor in Cancer Research, University of Salford Manchester, discusses predicting clinical response to immunotherapy agents for patients with mesothelioma.

Gastroesophageal cancer (GEC) is a complex disease, encompassing cancers with different histological and molecular subtypes. Growing insight into the molecular biology of GEC is poised to change the treatment landscape for this disease, although many questions remain unanswered.

Even with 1 FDA approval of an immunotherapeutic agent in urothelial carcinoma—and more expected in the coming months—chemotherapy regimens will continue to play a pivotal part in the treatment of patients with this disease.

Though testing for mutations in EGFR, ALK, and ROS1 is a standard approach in patients with non–small cell lung cancer, the same is not true for less common genetic abnormalities, including RET, BRAF, c-MET, and NTRK.

Three recent drug approvals have shifted the landscape in the second-line setting for renal cell carcinoma, and researchers are now setting their sights on transforming upfront care.

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the potential that immunotherapy may have in the treatment of patients with colorectal cancer.

Treatment with the PD-1 inhibitor nivolumab showed promising results in patients with recurrent malignant pleural mesothelioma.

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the novel approaches with immunotherapy that he would like to explore in the future treatment of patients with gynecologic cancers.

Although randomized phase III clinical trials often lead to groundbreaking drug approvals and offer novel therapeutic regimens, Maurie Markman, MD, insists that the search for validated, actionable biomarkers is more important than initiation of new studies.

Immunotherapy may be having a moment in the changing landscape of bladder cancer, but expert Gopa Iyer, MD, advises that there is much research to be done before physicians replace chemotherapy with these agents upfront.

The field of lung cancer has undoubtedly seen notable advances over the past year—especially with the game-changing November 2016 approval of pembrolizumab for the frontline treatment of patients with non–small cell lung cancer.

Beyond the strong efficacy outcomes observed with single-agent immunotherapies in non–small cell lung cancer—including pembrolizumab, nivolumab, and atezolizumab—the field is now awaiting the next phase: combination regimens.

Sara M. Tolaney, MD, MPH, associate director, Clinical Research, Breast Oncology, Susan F. Smith Center for Women's Cancers, senior physician, instructor in Medicine, Harvard Medical School, discusses a phase Ib/II trial exploring eribulin mesylate (Halaven) in combination with pembrolizumab (Keytruda) in patients with metastatic triple-negative breast cancer (TNBC).

The combination of pembrolizumab and eribulin demonstrated a 33.3% objective response rate for patients with metastatic triple-negative breast cancer who received 0 to 2 prior lines of therapy.

The FDA has granted a priority review to a biologics license application for the PD-L1 inhibitor durvalumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on standard platinum‑based chemotherapy.

Early data from a phase I/II study suggest that the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) may be an active and well-tolerated outpatient regimen in patients with relapsed/refractory classical Hodgkin lymphoma after failure of standard frontline chemotherapy.